Imunon reports Q1 net loss $4.3M; Phase 2 ovarian data shows 14.7-month OS improvement

Imunon, Inc.

• Net loss of $4.3M ($0.84 per share) vs $4.1M ($3.15 per share) in Q1 2025; cash $4.8M at March 31, 2026.
• Phase 2 OVATION 2 final data: median OS 45.1 vs 30.4 months (+14.7 months) for IMNN-001+SoC vs SoC alone.
• With PARP inhibitor maintenance, median OS 65.6 vs 41.4 months (+24.2 months) for IMNN-001 arm.
• Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on BLA path.
• Strategic reorganization in Feb 2026 reduced operating expenses; R&D expenses up to $2.3M from $2.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.